What is InProTher?
InProTher is at the forefront of developing innovative immunotherapies that target human endogenous retroviruses (HERVs). These retroviruses are implicated in various diseases, including cancer and aging-related conditions. By making these dormant antigens visible to the immune system, InProTher aims to enhance immune responses and unlock new therapeutic avenues. The company leverages a proprietary engineering platform to create off-the-shelf therapeutic assets designed for oncology, metabolic disorders, and longevity applications. Their work is driven by a team of seasoned researchers and drug developers focused on transforming treatments for complex diseases.
How much funding has InProTher raised?
InProTher has raised a total of $6.4M across 1 funding round:
Angel/Seed
$6.4M
Angel/Seed (2023): $6.4M with participation from The European Innovation Council
Key Investors in InProTher
The European Innovation Council
The European Innovation Council is an entity focused on fostering innovation, likely supporting early-stage and high-potential ventures within the European Union.
What's next for InProTher?
With this major enterprise-level funding, InProTher is poised for significant expansion and acceleration of its research and development pipeline. The strategic investment will likely fuel the advancement of its proprietary platform and the progression of its therapeutic candidates through clinical trials. This capital infusion signals strong confidence in InProTher's approach to tackling challenging diseases by harnessing the power of the immune system against HERVs, positioning the company for substantial growth and impact in the biopharmaceutical sector.
See full InProTher company page
